Does Blue Cross Blue Shield of Minnesota Cover Eliquis?

How BCBSMN Formulary Placement Affects Your Eliquis Cost

BCBSMN organizes covered drugs into tiers that determine what you pay at the pharmacy counter. Eliquis appears on most BCBSMN formularies as a Tier 3 preferred brand medication, though some employer-sponsored or individual plans classify it as Tier 4 non-preferred brand. The tier assignment directly controls whether you owe a flat copay (common on commercial PPO and HMO plans) or a percentage-based coinsurance (common on high-deductible health plans and Medicare Advantage products).

On a typical BCBSMN Blue Cross commercial PPO, a Tier 3 brand drug carries a copay between $35 and $75 per 30-day fill. High-deductible plans require you to pay the full negotiated rate until your deductible is met, which can mean a first-fill cost of $400 or more before cost-sharing kicks in. BCBSMN Medicare Advantage (Blue Cross Medicare Advantage) plans generally apply 25% to 33% coinsurance during the initial coverage phase, with costs dropping once you enter the Coverage Gap Discount Program phase [1]. The 2026 Medicare Part D redesign caps annual out-of-pocket drug spending at $2,000, which benefits patients on high-cost anticoagulants like Eliquis.

To confirm exactly which tier applies to your plan, log in to the BCBSMN member portal and search the formulary lookup tool, or call the number on the back of your member ID card. Formulary placement can shift at the start of each plan year.

Eliquis Prescribing Indications and Why Insurers Cover It

Eliquis earned FDA approval in 2012 for reducing stroke risk in patients with non-valvular atrial fibrillation (NVAF). The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared with warfarin (HR 0.79 to 95% CI 0.66 to 0.95, P=0.01) and lowered major bleeding by 31% (HR 0.69 to 95% CI 0.60 to 0.80, P<0.001) [1]. These results established Eliquis as a first-line direct oral anticoagulant (DOAC) recommended in the 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline [2].

Eliquis also carries approvals for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), based on the AMPLIFY trial (N=5,395), which showed non-inferior efficacy to standard enoxaparin-warfarin therapy with 69% less major bleeding (RR 0.31 to 95% CI 0.17 to 0.55, P<0.001) [3]. A third indication covers VTE prophylaxis after hip or knee replacement surgery, supported by the ADVANCE trials [4].

Because clinical guidelines from the ACC, AHA, ACCP, and the American College of Chest Physicians all position DOACs ahead of warfarin for most eligible patients, insurers including BCBSMN maintain formulary coverage. The cost-effectiveness data supports this: a 2021 analysis published in the Journal of Managed Care & Specialty Pharmacy found that apixaban-based anticoagulation reduced stroke-related hospitalizations enough to offset most of the drug acquisition cost differential versus warfarin [5].

Prior Authorization and Step-Therapy Rules at BCBSMN

Not every BCBSMN plan requires prior authorization (PA) for Eliquis, but several plan designs do apply utilization-management edits. The most common restriction is a quantity limit capping dispensing at 60 tablets per 30-day fill (matching the standard 5 mg twice-daily dose). Some plans also enforce a step-therapy protocol that asks whether the patient has tried or has a contraindication to warfarin before approving a DOAC.

If your claim is rejected at the pharmacy, the denial notice will specify the restriction type. You or your prescriber can then submit a coverage determination request, which BCBSMN must process within 72 hours for standard requests or 24 hours for expedited (urgent) requests under Minnesota statute and federal parity rules.

Your physician will need to document the clinical rationale. Accepted reasons typically include: history of labile INR on warfarin, inability to comply with regular INR monitoring, drug-drug interaction with warfarin (for example, concurrent use of amiodarone or fluconazole), or a prior adverse event on warfarin. In the ARISTOTLE population, the intracranial hemorrhage rate with apixaban was 0.33% per year versus 0.80% with warfarin [1]. Citing this safety advantage often strengthens an appeal.

BCBSMN publishes its clinical coverage policies online. Search "anticoagulant" on the BCBSMN medical policy page to find the current criteria document for your plan type.

How to Reduce Your Out-of-Pocket Eliquis Cost with BCBSMN

Even with insurance coverage, the copay for a brand-name anticoagulant can be substantial. Several strategies can bring your cost down.

Manufacturer copay assistance. Bristol-Myers Squibb offers the Eliquis 360 Support Program copay card for commercially insured patients. Eligible members may pay as little as $10 per 30-day fill, with the program covering up to a specified annual maximum. This card cannot be used with Medicare, Medicaid, or other federal programs.

BCBSMN mail-order pharmacy. Many BCBSMN plans offer a 90-day supply at a reduced cost-per-day rate through their preferred mail-order pharmacy (Prime Therapeutics or a contracted specialty pharmacy). Switching from retail to mail-order can cut the per-tablet cost by 10% to 20%.

Medicare Extra Help (LIS). If you are enrolled in a BCBSMN Medicare Advantage plan and your income is below 150% of the federal poverty level, you may qualify for the Medicare Part D Low-Income Subsidy. This program caps copays at $4.50 for generic drugs and $11.20 for brand-name drugs in 2026.

Patient assistance programs. Patients without insurance or with coverage gaps may apply to the Bristol-Myers Squibb Patient Assistance Foundation, which provides Eliquis at no cost to qualifying individuals whose household income falls below 300% of the federal poverty level.

Formulary exception request. If BCBSMN places Eliquis on a higher tier than expected, your prescriber can submit a formulary tier exception request arguing medical necessity. Under the ACA and Minnesota insurance regulations, BCBSMN must review these requests and respond within the statutory timeframe.

BCBSMN Plan Types and How Each Handles Eliquis

BCBSMN offers multiple product lines, and Eliquis coverage details vary by plan category. Understanding which plan you carry determines your cost-sharing and access rules.

Commercial PPO and HMO. These employer-sponsored or individual-market plans typically list Eliquis on Tier 3 with a fixed copay. HMO plans may restrict you to an in-network pharmacy, while PPO plans allow out-of-network fills at a higher cost. Both plan types usually do not require PA for standard Eliquis doses.

Blue Cross Medicare Advantage (MA-PD). Medicare Advantage plans with Part D coverage apply the CMS-mandated coverage phases: deductible, initial coverage, coverage gap, and catastrophic. The 2026 $2,000 out-of-pocket cap means most Eliquis users will reach catastrophic coverage within approximately four to five months of fills at retail price. After that threshold, you pay $0 for the remainder of the plan year.

Minnesota Health Care Programs (MHCP/Medical Assistance). Patients enrolled in Medicaid managed care through BCBSMN (such as the Blue Plus product) follow the MHCP preferred drug list. Eliquis is generally accessible, though the state formulary may impose its own PA criteria separate from the commercial formulary.

ACA Marketplace (MNsure). Individual and family plans purchased through MNsure and administered by BCBSMN follow ACA essential health benefit rules, which require prescription drug coverage. Eliquis is included, though silver and bronze plans often carry higher cost-sharing than gold plans.

Each plan type publishes its own formulary document, updated annually and sometimes mid-year. Always verify your specific plan before assuming a particular tier or copay amount.

Eliquis vs. Other Anticoagulants on the BCBSMN Formulary

BCBSMN covers several anticoagulant options, and your formulary tier, copay, and PA requirements may differ across them. Knowing the alternatives helps if a step-therapy edit or cost barrier affects your Eliquis access.

Warfarin remains the lowest-cost option because multiple generic manufacturers produce it. A 30-day supply typically costs $4 to $15 even without insurance. BCBSMN places warfarin on Tier 1 (generic). The trade-off: warfarin requires regular INR monitoring (typically every 2 to 4 weeks), has numerous food and drug interactions, and carries a higher intracranial hemorrhage risk than DOACs [1].

Xarelto (rivarelbán) sits on a similar tier to Eliquis at most BCBSMN plans. The ROCKET AF trial (N=14,264) showed rivarelbán was non-inferior to warfarin for stroke prevention, but it did not demonstrate the major-bleeding reduction that ARISTOTLE showed for apixaban [6]. Once-daily dosing is an advantage for some patients. However, rivarelbán requires intake with a meal for adequate absorption, and its 20 mg dose has limited dose-adjustment options compared with apixaban.

Savaysa (edoxaban) occupies a smaller market share and may appear on a higher tier or require PA at BCBSMN. The ENGAGE AF-TIMI 48 trial (N=21,105) supported its approval, though it is not recommended for patients with creatinine clearance greater than 95 mL/min [7].

The 2023 ACC/AHA guideline states: "DOACs are recommended over warfarin in DOAC-eligible patients with AF" (Class 1, Level of Evidence A) [2]. Among DOACs, the guideline does not declare a single preferred agent, but notes that apixaban "demonstrated superiority in both efficacy and safety endpoints" in ARISTOTLE. This language can support a formulary exception if BCBSMN restricts Eliquis access on your particular plan.

Filing an Appeal If BCBSMN Denies Eliquis Coverage

A denial does not mean the answer is final. Minnesota law (Minn. Stat. §62Q.73) and federal regulations grant you the right to appeal any adverse coverage determination. The process has defined steps.

First, request the denial in writing. BCBSMN must provide a written explanation including the clinical rationale and the specific policy provision cited. Second, your prescriber submits a peer-to-peer review or a written letter of medical necessity. This letter should reference trial data (ARISTOTLE, AMPLIFY), guideline recommendations (ACC/AHA 2023), and patient-specific factors such as renal function, fall risk, bleeding history, or inability to maintain therapeutic INR on warfarin.

Third, if the internal appeal is denied, you can request an external review through the Minnesota Department of Commerce. An independent review organization (IRO) examines the case and renders a binding decision, typically within 45 days for standard reviews or 72 hours for expedited reviews involving urgent clinical need [8].

According to a 2023 KFF analysis, approximately 50% of internal insurance appeals for prescription drugs result in full or partial reversal of the original denial. The success rate rises when the appeal includes published clinical evidence and a letter from the treating cardiologist or hematologist.

Dosing, Renal Adjustments, and Quantity Limit Implications

Standard Eliquis dosing for atrial fibrillation is 5 mg taken twice daily. The FDA-approved labeling specifies a reduced dose of 2.5 mg twice daily for patients meeting at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [9]. For DVT/PE treatment, the regimen starts at 10 mg twice daily for 7 days, then steps down to 5 mg twice daily.

BCBSMN quantity limits are calibrated to the maintenance dose (60 tablets per 30 days for the 5 mg strength). If your prescriber writes a loading-dose script (10 mg twice daily for 7 days, equaling 28 tablets of 5 mg in the first week), the pharmacy may need to process a quantity-limit override. This is a routine request and is usually approved within 24 hours when the prescriber notes "DVT/PE acute treatment per FDA labeling."

Renal dosing matters for both safety and coverage. Patients with end-stage renal disease (eGFR <15 mL/min) or on dialysis were excluded from major trials [1][3]. The FDA label permits use in this population based on pharmacokinetic modeling, but some payers request additional justification. If BCBSMN flags a renal-dose claim, your prescriber should document the patient's eGFR, weight, and age alongside the clinical rationale.

What Minnesota State Law Requires from BCBSMN

Minnesota has several statutes that shape how BCBSMN must handle prescription drug coverage decisions. Minn. Stat. §62Q.81 requires health plan companies to maintain a process for formulary exceptions that includes response within 24 hours for urgent requests. Minn. Stat. §62Q.73 mandates internal and external appeal rights for any adverse determination, including step-therapy overrides.

The Minnesota Department of Commerce oversees insurance regulatory compliance. If you believe BCBSMN has improperly denied Eliquis coverage, you can file a complaint online or by phone. The Department investigates whether the denial followed the plan's published criteria and state law.

A 2024 Minnesota legislative update also requires insurers to provide real-time pharmacy benefit information, meaning your prescriber's electronic health record system should display your Eliquis copay estimate at the point of prescribing. If this information is not available, ask your pharmacist to run a test claim before filling.

BCBSMN must also comply with the federal No Surprises Act and the Transparency in Coverage rule, which requires publication of machine-readable files listing negotiated drug prices. These files, available on the BCBSMN website, can help you verify the plan's contracted rate for Eliquis before you fill.